PC23537B Response to Office Action Certificate of Mailing (37 C.F.R. §1.8):
I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:
Mail Stop: Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 20th day of May 2005.



s/ Kly Horax

Group Art Unit: 1623

Examiner: Paul V. Ward

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: PENG CHO TANG, et al.

·

Confirmation No.: 3943

Serial No.: 10/648,810

Filed: August 27, 2003

For:

4-HETEROARYL-3-

HETEROARYLIDENYL-2-

INDOLINONES AND THEIR USE AS PROTEIN KINASE INHIBITORS

Mail Stop: Amendment Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

1. Response to Office Action

11 pages;

2. Transmittal Letter

1 page; and

3. Total Fee Due \$0.00

Deposit Account.

Date: 05/25/125

Respectfully submitted,

Vincent P. Liptak, Ph.D. Agent For Applicants Registration No. 53,225

Agouron Pharmaceuticals, Inc./A Pfizer Company Patent Department 10777 Science Center Drive San Diego, California 92121

Phone: (858) 622-7908 Fax: (858) 678-8233

PC23537B Response to Office Action



Certificate of Mailing (37 C.F.R. §1.8):

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 20th day of May 2005.

Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Peng Cho Tang, et al.

Serial No.: 10/648,810

Confirmation No.: 3943

Filed: August 27, 2003

For:

4-HETEROARYL-3-

HETEROARYLIDENYL-2-

INDOLINONES AND THEIR USE AS PROTEIN KINASE INHIBITORS

Group Art Unit: 1623

Examiner: Paul V. Ward

Mail Stop AMENDMENT Honorable Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE

Sir:

In response to the Office action mailed February 22, 2005, please amend the aboveidentified application as follows:

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks begin on page 9 of this paper.